Clinical First-in-Human Single-Dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-Center, Phase I, Open-Label, i.v. Infusion Study.

Trial Profile

Clinical First-in-Human Single-Dose Escalation Study Evaluating the Safety and Tolerability of Claudiximab (iMAB-362) in Hospitalized Patients With Advanced Gastroesophageal Cancer. A Multi-Center, Phase I, Open-Label, i.v. Infusion Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Zolbetuximab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Ganymed Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2018 Results published in the European Journal of Cancer.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 31 Aug 2017 According to a Astellas Pharma media release, new data from this study will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top